Sphera Funds Management’s Arbutus Biopharma ABUS Stock Holding History

Sphera Funds Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-500,000	Closed	-$763K	–	87
2019 Q3	$763K	Hold	500,000	–	–	0.12%	74
2019 Q2	$1.04M	Buy	+500,000	New	+$1.28M	0.14%	78
2018 Q4	–	Sell	-40,000	Closed	-$378K	–	102
2018 Q3	$378K	Buy	+40,000	New	+$397K	0.04%	103
2017 Q1	–	Sell	-22,000	Closed	-$54K	–	113
2016 Q4	$54K	Sell	22,000 -278,000	-93%	-$809K	0.01%	103
2016 Q3	$1.03M	Hold	300,000	–	–	0.17%	93
2016 Q2	$1.04M	Sell	300,000 -154,500	-34%	-$654K	0.27%	77
2016 Q1	$1.88M	Hold	454,500	–	–	0.41%	55
2015 Q4	$2.02M	Sell	454,500 -50,500	-10%	-$277K	0.3%	84
2015 Q3	$3.08M	Buy	505,000 +250,000	+98%	+$2.22M	0.39%	56
2015 Q2	$3.02M	Sell	255,000 -43,486	-15%	-$662K	0.3%	88
2015 Q1	$5.21M	Buy	298,486 +123,486	+71%	+$2.53M	0.54%	37
2014 Q4	$2.65M	Buy	+175,000	New	+$3.02M	0.45%	76

Other funds holding ABUS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sphera Funds Management's ABUS Position: Q4 2019 in Review

Sphera Funds Management sold out of Arbutus Biopharma (ABUS) in Q4 2019, closing a stake of 500,000 shares — an estimated $763K sold.

Sphera Funds Management first reported a position in ABUS in Q4 2014 and held it in 12 quarters. The position peaked at $5.21M in Q1 2015. 59 funds tracked by Wall St. Rank hold ABUS as of Q4 2019.

Sphera Funds Management reported no remaining Arbutus Biopharma position as of Q4 2019 after selling out during the quarter.
Sphera Funds Management sold 500,000 Arbutus Biopharma shares in Q4 2019, an estimated $763K.
Sphera Funds Management first reported a position in Arbutus Biopharma in Q4 2014 and held it in 12 quarters.
Sphera Funds Management's Arbutus Biopharma position peaked at $5.21M in Q1 2015.
59 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2019.

Based on Sphera Funds Management's 13F filing for Q4 2019, filed 13 Feb 2020.